Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GTXI

GTX (GTXI) Stock Price, News & Analysis

GTX logo

About GTX Stock (NASDAQ:GTXI)

Advanced Chart

Key Stats

Today's Range
$0.53
$0.53
50-Day Range
$1.20
$7.20
52-Week Range
$0.74
$25.60
Volume
N/A
Average Volume
390,540 shs
Market Capitalization
$12.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive GTXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter.

GTXI Stock News Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Garrett Motion to present electrification solutions at Auto Shanghai
Did Nvidia peak with the GTX 10 series?
See More Headlines

GTXI Stock Analysis - Frequently Asked Questions

GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.09.

Based on aggregate information from My MarketBeat watchlists, some other companies that GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), SELLAS Life Sciences Group (SLS), Verastem (VSTM), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/15/2018
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GTXI
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.48

Miscellaneous

Free Float
N/A
Market Cap
$12.66 million
Optionable
Not Optionable
Beta
2.22
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:GTXI) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners